Spur Therapeutics’ Post

View organization page for Spur Therapeutics, graphic

9,839 followers

Today, we announced positive new data from our #GBA1 #Parkinson’s disease research program. These data were presented at the inaugural GBA1 Meeting in Montreal. There is a rapidly emerging understanding of the role GBA1 mutations play in neurodegenerative diseases and much to learn. We were thrilled to be part of the inaugural meeting and share its aim to advance the understanding and treatment of GBA1 PD. https://lnkd.in/gsfuDKff

Spur-Therapeutics-GBA1-PD-Press-Release-07-01-2024.pdf

spurtherapeutics.com

Julia P. Gregory

Chair and CEO, Isometry Advisors, Independent Director

1mo

Congratulations on this important step!

To view or add a comment, sign in

Explore topics